D-serine added to antipsychotics for the treatment of schizophrenia.
Quick navigation
Link to full study
http://www.ncbi.nlm.nih.gov/pubmed/9836012
Conclusion of this study
The significant improvement with the D-serine further supports the hypothesis of NMDA receptor hypofunction in schizophrenia. Given the effects of D-serine on positive symptoms, a trial of D-serine alone in schizophrenia should be considered.
Supplements analyzed in this study
Health conditions analyzed in this study
Functions related to this study
Body systems related to this study
